September 2022 Activities Report and Appendix 4C

Key points:

- **Strong cash balance of $21.9 million following recent Share Purchase Plan and Top-Up Placement**
- **Unveiling of CellPryme-A, an adjuvant therapy platform that enhances tumour killing of cellular therapies and host survival**
- **Strategic collaboration announced with MD Anderson Cancer Centre in the US**
- **Q-Gen appointed for OmniCAR T cell manufacturing for clinical trials**
- **Extending the OmniCAR platform with non-viral transduction and automated manufacturing**
- **FDA Orphan Drug status received for PTX-100 to treat Peripheral T-cell lymphoma**
- **Key OmniCAR patent granted in the US**

MELBOURNE Australia, 31 October 2022 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, today reported its September 2022 quarter results and operating highlights.

It was an especially productive quarter for the Company, achieving a number of important and value-adding milestones across several aspects of its business.

Financial summary

Prescient ended the September quarter with a cash balance of $10.6 million. Subsequent to the quarter end, on 7 October 2022 the Company completed a Share Purchase Plan ("SPP") that raised gross proceeds of $8.8 million and in excess of the targeted $8 million. On 11 October 2022, the Company completed a Top-Up Placement that raised gross proceeds of $2.5 million. The SPP and Top-Up Placement increased the Company's cash reserves to $21.9 million.

Costs for the quarter were driven by ongoing clinical programs and manufacturing for PTX-100 and PTX-200, OmniCAR cell therapy platform development and the recently announced high-performance cell therapy manufacturing technology CellPryme-M.

Total cash outflows for the quarter were in line with the previous quarter at $1.8 million, with approximately $1.0 million committed to research and development in Australia and the United States. Payments during the period to related parties of the entity and associates were $158,000. These payments relate to non-executive director fees, and salary and superannuation for the CEO and Managing Director.

As always, management maintains astute oversight of operating costs whilst developing multiple programs.

CellPryme-A unveiled: advancing the efficacy of existing CAR-T therapies

Prescient's new cell therapy enhancement platform, CellPryme-A, was recently unveiled by Senior Vice President of Scientific Affairs, Dr Rebecca Lim at the annual CAR-TCR Summit in Boston. CellPryme-A is an adjuvant therapy administered to cancer patients in combination with cellular immunotherapy and address the hostile tumour microenvironment that reduce the effectiveness of cellular immunotherapies.

CellPryme-A boosts the tumour killing capabilities of CAR-T therapies and improves host survival in highly resistant, syngeneic animal models. It does this by reducing the number of suppressive regulatory T cells surrounding solid tumours that counteract the effectiveness of CAR-T and other cancer therapies; dramatically enhancing CAR-T expansion *in vivo* and increasing CAR-T cell penetration into tumours. The beneficial effects were even greater when CellPryme-A was used in combination with CAR-T cells that incorporated CellPryme-M into their manufacturing process.

Although only recently disclosed, both CellPryme technologies have started to generate strong interest among the international clinical community and doctors working to overcome the limitations of current CAR-T therapies. Both CellPryme technologies are ready for clinical trials, with suitable material readily available.

Another partnership with a world-leading cancer centre

A major milestone this quarter was the announcement of a strategic collaboration with the largest cancer centre in the US, The University Texas MD Anderson Cancer Centre (MD Anderson) to deliver best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. This collaboration with MD Anderson continues Prescient's track record of partnering with world-leading cancer research organisations.

The collaboration will combine Prescient's OmniCAR modular 'plug and play' CAR platform with an undisclosed, proprietary TCR-like binder discovered by MD Anderson's Evolution of Leukemia and

Immunity Post Stem cEll transplant platform, also known as ECLIPSE. The ECLIPSE platform yielded unique binders to novel targets that had previously been hidden inside cancer cells.

The collaboration will initially focus on a unique TCR-like binder to an undisclosed target present on leukemic blasts and leukaemic stem cells, whose expression correlates strongly with poor outcomes. MD Anderson's unique binder can be used in combination with Prescient's CD33 and CLL-1 binders and has the potential to result in synergies including increased efficacy and a broader spectrum of cancer killing.

OmniCAR cells and binders will be manufactured and tested by the ECLIPSE team at MD Anderson with the costs and ownership of the resultant therapeutic product shared equally.

The strategic collaboration consolidates Prescient at the forefront of cellular immunotherapy and creating an adaptable cell therapy ecosystem of cells and binders enabled by OmniCAR,

Manufacturing agreement to ensure supply for pending OmniCAR clinical studies

During the quarter Prescient entered a manufacturing services agreement with specialist cell therapy manufacturer, Q-Gen Cell Therapeutics (Q-Gen), to produce its OmniCAR cell lines for upcoming clinical trials. The Company announced that the OmniCAR AML program is likely be the first OmniCAR program to enter clinical studies.

Manufacturing will take place at Q-Gen's dedicated Brisbane facility, which produces autologous and allogeneic cell therapies for local and international pharmaceutical companies and academic research groups. Q-Gen is the cell therapy manufacturing arm of the QIMR Berghofer Medical Research Institute and is one of Australia's leading producers of cell-based medicines. Prescient has commenced the technology transfer process for OmniCAR-T cell manufacturing.

Q-Gen will also incorporate Prescient's cell manufacturing enhancement, CellPryme-M into the manufacturing process of OmniCAR T cells, to produce a more effective and longer lasting T cell phenotype.

OmniCAR platform extensions for more efficient and reproducible manufacturing

During the quarter, Prescient announced a material transfer agreement with a large international company to evaluate the potential of utilizing an automated, closed process for manufacturing OmniCAR T cells using non-viral methods.

A key objective for Prescient is to manufacture OmniCAR with greater efficiency, higher reproducibility and lower costs that are suitable for technology transfer to third party manufacturers. This aligns with Prescient's vision of decentralized manufacturing which is ideally suited for multi-centre studies and eventually for commercial roll-out.

PTX-100 receives Orphan Drug Designation from US FDA

Prescient's targeted cancer therapies PTX-100 and PTX-200 continued to deliver positive clinical and commercial milestones.

During the quarter, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to PTX-100 as a treatment for peripheral T-cell lymphomas, a hard to treat blood cancer.

The designation gives special status to drugs intended for the treatment of rare diseases that affect fewer than 200,000 people in the US. The benefits include a guaranteed market for seven years after regulatory approval and a waiver of Prescription Drug User Fee Act (PDUFA) fees once the drug is on the market.

PTX-100 showed an encouraging efficacy signal in PTCL in the dose escalation of a Phase 1b basket study, and is now in an expansion cohort of 12 patients with relapsed and refractory T cell lymphomas (TCL), including PTCL, under the leadership of globally-renowned lymphoma expert, Professor H. Miles Prince, AM. The expansion cohort is due to fully recruit this year.

Key OmniCAR patent granted in US

During the quarter a key patent in the OmniCAR portfolio was granted in the US. The granting of US Patent No 11,377,481 entitled "*SpyCatcher and SpyTag: Universal Immune Receptor For T* Cells" provides protection for the Company's valuable intellectual property in the world's largest healthcare market until 2039.

Maintaining momentum across the portfolio

Prescient acknowledges the ongoing support of its shareholders who have made the advances this quarter possible.

This report is a summary of the Company's progress over the past quarter. The Board and Management remain focused on maximizing the value of these significant clinical achievements, assets and partnerships for the benefit of medical professionals and their patients with hard-to-treat cancers.

The Appendix 4C - Quarterly Cash Flow Report for the September 2022 quarter is attached.

- Ends -

To stay updated with the latest company news and announcements, please update your details on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia.

Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound is currently in a Phase 1b/2 trial in relapsed and refractory AML, where it has resulted in 4 complete remissions so far. PTX-200 previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn.

Steven Yatomi-Clarke	**Investor enquiries:**	**Media enquiries:**
CEO & Managing Director	Sophie Bradley – Reach Markets	Andrew Geddes – CityPR
Prescient Therapeutics	+61 450 423 331	+61 2 9267 4511
steven@ptxtherapeutics.com	ir@reachmarkets.com.au	ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

Supplemental COVID-19 Risk Factors

Please see our website : Supplemental COVID-19 Risk Factors

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Prescient Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
56 006 569 106	30 September 2022

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(956)	(956)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(201)	(201)
	(f) administration and corporate costs	(648)	(648)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	30	30
1.5	Interest and other costs of finance paid	-	
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	50	50
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,725)**	**(1,725)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment		
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**		

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	47	47
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**47**	**47**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	12,264	12,264
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,725)	(1,725)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	47	47
4.5	Effect of movement in exchange rates on cash held	6	6
4.6	**Cash and cash equivalents at end of period**	**10,592**	**10,592**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,592	2,264
5.2	Call deposits	6,000	10,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**10,592**	**12,264**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	158
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,725)
8.2	Cash and cash equivalents at quarter end (item 4.6)	10,592
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	10,592
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	6.1

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: N/A

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2022

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.